Tirzepatide-induced Weight Loss in Overweight or Obese Midlife Adults with and without Type 2 Diabetes: A Real-world Comparative Cohort Study.

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist, has demonstrated robust weight loss and glycemic benefits in randomized controlled trials. However, real-world data comparing its effectiveness and tolerability in obese adults with and without type 2 diabetes (T2D) are limited. The present study aimed to evaluate the real-world short-term effectiveness and safety of tirzepatide in promoting weight loss among obese or overweight adults with and without T2D.